Honasa buys majority stake in Fluence Pharma, betting on health-beauty convergence

Mamaearth parent Honasa Consumer has acquired a majority stake in Fluence Pharma, pushing into nutraceuticals and prescription-led segments. The deal signals Indian BPC brands' pivot toward health-beauty convergence to build consumer trust and unlock new growth avenues.

— Source publishedMon, 29 Jun, 2026, 13:04 IST·First seen Mon, 29 Jun, 2026, 13:08 IST·Source Mint · Companies

What happened

Mamaearth (Honasa Consumer) · Honasa Consumer (Mamaearth parent) acquired a majority stake in Fluence Pharma, entering nutraceuticals and signaling Indian BPC

Key facts

  • majority stake

Why this matters

This majority-stake deal validates health-beauty convergence as the active M&A thesis for Indian BPC brands—expect more nutraceutical and pharma-adjacent targets to come into play.

What to watch

  • Honasa quarterly disclosure of Fluence revenue contribution and margin impact
  • Launch of co-branded ingestible-beauty SKUs and pricing
  • Competitor M&A announcements in nutraceuticals/health-beauty
  • Regulatory signals from FSSAI/CDSCO on nutraceutical and cosmeceutical claims
  • Gross margin trajectory and integration cost callouts in next two earnings calls
  • Cross-sell Fluence nutraceuticals through Mamaearth/Derma Co. D2C and quick-commerce channels
  • Build dermatologist and clinical-claim marketing to differentiate ingestible-plus-topical regimens
  • Pursue chemist/pharmacy distribution access to offset offline retail gaps
  • Bolt-on acquisitions in supplements or clinical skincare to deepen the convergence thesis

Also reported by